

Press release
December 21, 2020

Results from Phase II study in prostate cancer to be published in the Journal of Nuclear Medicine

As previously communicated in connection with the IPO the results from the phase II study performed by researchers at Rigshospitalet were available in 2020. Following data analysis, a scientific manuscript covering the results has been submitted by the research group to the Journal of Nuclear Medicine where it underwent a stringent peer-review process. Following this process, the manuscript has been accepted for publication in an upcoming issue of the Journal of Nuclear Medicine probably during H1 2021.

The phase II study

The aim of the phase II study was to evaluate the correlation between uptake on uPAR-PET with ⁶⁸Ga-NOTA-AE105 (uTRACE®) and Gleason Score in prostate cancer patients undergoing prostate biopsy. SUV*) measurements from uPAR PET in primary tumors as delineated by mpMRI showed a significant correlation with Gleason score, and tumor SUVmax was able to discriminate between low-risk and intermediate risk Gleason score profiles with high diagnostic accuracy. Consequently, uPAR PET/MRI could be a promising method for non-invasive evaluation of prostate cancer, which may in the future potentially reduce the need for repeated biopsies, e.g. in active surveillance.

About the Journal of Nuclear Medicine

The Journal of Nuclear Medicine is the official publication of the Society for Nuclear Medicine and Molecular Imaging and the highest ranked journal within nuclear medicine based on number of citations (impact factor). Before the final version of the article can be published, it will undergo copyediting, proofreading and author review, which may lead to some differences between the accepted and final, published version. Once the final version is published, this will be communicated.

"We are of course very pleased that the results from the study from Rigshospitalet will be published in the Journal of Nuclear Medicine, as this underscores the quality and impact of the study. Furthermore and as previously communicated, the study has demonstrated a first proof-of-concept for the idea of using uPAR-PET as a non-invasive measure of cancer aggressiveness in prostate cancer. We believe this supports the potential of using imaging for saving some of the biopsies currently taken. Curasight will take this information into consideration together with other factors as part of our work towards developing an optimal design of a future Curasight sponsored phase III study. Such a design will also be discussed with and guided by input from key opinion leaders within prostate cancer" says CEO Ulrich Krasilnikoff.

*) Standardized uptake value (SUV) is a measure of PET tracer concentration. SUVmax is a measure of the maximal value of SUV within a certain region, e.g. within the volume of a tumor. Gleason score is a grading system of prostate cancer aggressiveness based on pathological evaluation of tissue from the tumor.

For more information regarding Curasight, please contact:

Ulrich Krasilnikoff, CEO
Phone: +45 22 83 01 60
E-mail: uk@curasight.com
www.curasight.com

Curasight is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor ("uPAR"). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.